Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
87 articles
(Page 3)
Rucaparib's Promise: New Hope for Recurrent Ovarian Cancer Patients
Meta-analysis reveals rucaparib's efficacy in treating recurrent ovarian cancer, especially in BRCA carriers.
Dual Checkpoint Inhibition Shows Promise in Rare Desmoid Tumors
Phase II trial reveals potential of ipilimumab and nivolumab combination in treating desmoid tumors
Weekly Cisplatin: A Kidney-Friendly Approach for Head and Neck Cancer Treatment
Study finds weekly cisplatin reduces kidney injury risk without compromising survival in head/neck cancer.
Immunotherapy Rechallenge Falls Short in Advanced Kidney Cancer Trial
Phase 3 trial shows no benefit of adding immune checkpoint inhibitor to targeted therapy in RCC patients
INSIGHT Trial: Tailoring GIST Treatment with Precision Medicine
New trial evaluates ripretinib vs sunitinib in advanced GIST patients with specific KIT mutations
Pembrolizumab Boosts Survival in Early-Stage Melanoma: KEYNOTE-716 Trial Results
Adjuvant pembrolizumab shows sustained benefits for stage IIB/IIC melanoma patients in phase III trial.
Warming Up to Scalp Cooling: Electric Hand Warmers Boost Comfort for Breast Cancer Patients
Study shows electric hand warmers improve comfort for breast cancer patients using scalp cooling during chemo
Triplet Chemotherapy Shows Promise in Advanced Gastric Cancer: MATCH Trial Results
DOS chemotherapy improves tumor response in locally advanced gastric cancer compared to SOX regimen
PARP Inhibitor Shows Promise in Delaying Prostate Cancer Progression
Study explores rucaparib as ADT-sparing option for nonmetastatic prostate cancer with DNA repair defects
Ramucirumab Shows Promise After Immunotherapy in Advanced Gastroesophageal Cancer
Study suggests ramucirumab may benefit certain patients with advanced gastroesophageal cancer after immunotherapy
Breakthrough Combo Therapy Revolutionizes Advanced Bladder Cancer Treatment
New drug combination shows superior survival benefit for advanced bladder cancer in global trial.
Prostate Cancer Immunotherapy Combo Falls Short in Phase 2 Trial
AZD4635 with durvalumab or oleclumab shows limited efficacy in metastatic castration-resistant prostate cancer